PIPE 791
Alternative Names: PIPE-791Latest Information Update: 28 Jul 2026
At a glance
- Originator Pipeline Therapeutics
- Developer Contineum Therapeutics
- Class Analgesics; Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
- Phase I Multiple sclerosis; Pain
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in USA (PO)
- 28 Jul 2026 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in USA (PO)
- 30 Apr 2026 Efficacy and adverse events data from a phase Ib trial in Pain released by Contineum Therapeutics